Physician profile
Edward J Wladis
NPI 1417992611
$179,058.89
in general payments reported to CMS, 2019-2025
13 companies · $20K in 2025
The $20K reported for 2025 was more than what 94% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.42 · 2020: $23K · 2021: $35K · 2022: $48K · 2023: $22K · 2024: $31K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Honoraria: $21K · Consulting Fee: $12K · Travel and Lodging: $3,092 · Food and Beverage: $2,966 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,600.00 |
| Honoraria | $20,625.00 |
| Consulting Fee | $12,337.50 |
| Travel and Lodging | $3,092.13 |
| Food and Beverage | $2,965.65 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $126,292.92 | 2019-2023 | Tepezza |
| Amgen INC. | $50,329.36 | 2024-2025 | Tepezza, Uplizna |
| Medical Device Business Services, INC. | $1,262.50 | 2020 | |
| Bausch & Lomb Americas INC. | $407.68 | 2023-2025 | Vyzulta, Xipere, Miebo |
| Tarsus Pharmaceuticals, INC. | $212.66 | 2024-2025 | Xdemvy |
| Merz Pharmaceuticals, LLC | $121.55 | 2022-2025 | Xeomin |
| Allergan, INC. | $119.85 | 2020 | |
| Ani Pharmaceuticals, INC. | $106.79 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $99.99 | 2023 | Acthar |
| Depuy Synthes Sales INC. | $37.29 | 2022 | |
| Dompe US, INC. | $34.30 | 2025 | Oxervate |
| Stryker Corporation | $17.50 | 2022 | |
| Kls-Martin L.P. | $16.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Wladis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.